UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis

Cancer medicine (Malden, MA), 2020-09, Vol.9 (17), p.6216-6224

2020

Volltextzugriff (PDF)

Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Cancer, 2001-07, Vol.92 (2), p.406-413

2001

Volltextzugriff (PDF)

A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS2695-TPS2695

2024

Volltextzugriff (PDF)

In Vitro Evaluation of Cytochrome P450-mediated Drug Interactions between Cytarabine, Idarubicin, Itraconazole and Caspofungin

Hematology (Luxembourg), 2004-06, Vol.9 (3), p.217-221

2004

Volltextzugriff (PDF)

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors

Clinical cancer research, 2011-09, Vol.17 (17), p.5774-5782

2011

Volltextzugriff (PDF)

Body weight-supported treadmill training vs. overground walking training for persons with chronic stroke: a pilot randomized controlled trial

Clinical rehabilitation, 2014-09, Vol.28 (9), p.873-884

2014

Volltextzugriff (PDF)

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

British journal of haematology, 2019-05, Vol.185 (3), p.595-598

2019

Volltextzugriff (PDF)

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF V600 Mutation-Positive Metastatic Malignancy

Journal of clinical pharmacology, 2018-08, Vol.58 (8), p.1067-1073

2018

Volltextzugriff (PDF)

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Cancer chemotherapy and pharmacology, 2017-07, Vol.80 (1), p.29-36

2017

Volltextzugriff (PDF)

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy

Journal of clinical pharmacology, 2018-08, Vol.58 (8), p.1067-1073

2018

Volltextzugriff (PDF)

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.1907-1907

2019

Volltextzugriff (PDF)

Skin Infiltration with Chronic Lymphocytic Leukemia is Consistent with a Good Prognosis

Hematology (Luxembourg), 2002, Vol.7 (3), p.187-188

2002

Volltextzugriff (PDF)

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

Cancer chemotherapy and pharmacology, 2003-09, Vol.52 (3), p.229-234

2003

Volltextzugriff (PDF)

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Cancer chemotherapy and pharmacology, 2016-07, Vol.78 (1), p.41-49

2016

Volltextzugriff (PDF)

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

British journal of clinical pharmacology, 2012-11, Vol.74 (5), p.788-796

2012

Volltextzugriff (PDF)

Absolute Bioavailability of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies

Clinical pharmacology in drug development, 2020-05, Vol.9 (4), p.496-504

2020

Volltextzugriff (PDF)

Abstract CT308: Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic dysfunction

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT308-CT308

2015

Volltextzugriff (PDF)

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

Journal of thoracic oncology, 2014-09, Vol.9 (9), p.1411-1417

2014

Volltextzugriff (PDF)

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies

Clinical pharmacology in drug development, 2020-05, Vol.9 (4), p.496-504

2020

Volltextzugriff (PDF)

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Investigational new drugs, 2003-02, Vol.21 (1), p.109-111

2003

Volltextzugriff (PDF)

Poster 75 Body Weight-Supported Treadmill Training vs. Over-Ground Walking Training for Persons With Chronic Stroke: A Randomized Controlled Trial

Archives of physical medicine and rehabilitation, 2012-10, Vol.93 (10), p.e36-e36

2012

Volltextzugriff (PDF)

Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential

Cancer chemotherapy and pharmacology, 2013, Vol.71 (1), p.193-202

2013

Volltextzugriff (PDF)

Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B188-B188

2011

Volltextzugriff (PDF)

Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1310-1310

2011

Volltextzugriff (PDF)

Shame, guilt, symptoms of depression, and reported history of psychological maltreatment

Child abuse & neglect, 2007-11, Vol.31 (11), p.1143-1153

2007

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

Humans
(24)
Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Female
(18)
Male
(17)
Middle Aged
(10)
Biological And Medical Sciences
(9)
Oncology
(9)
Adult
(8)
Aged
(8)
Adolescent
(7)
Cohort Studies
(7)
Medical Sciences
(7)
Anilides - Administration & Dosage
(6)
Child
(6)
Pharmacology & Pharmacy
(6)
Pharmacology. Drug Treatments
(6)
Pyridines - Administration & Dosage
(6)
Anilides - Pharmacokinetics
(5)
Cataract Extraction - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis

Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers

In Vitro Evaluation of Cytochrome P450-mediated Drug Interactions between Cytarabine, Idarubicin, Itraconazole and Caspofungin

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors

Body weight-supported treadmill training vs. overground walking training for persons with chronic stroke: a pilot randomized controlled trial

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF V600 Mutation-Positive Metastatic Malignancy

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Skin Infiltration with Chronic Lymphocytic Leukemia is Consistent with a Good Prognosis

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

Absolute Bioavailability of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies

Abstract CT308: Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic dysfunction

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Poster 75 Body Weight-Supported Treadmill Training vs. Over-Ground Walking Training for Persons With Chronic Stroke: A Randomized Controlled Trial

Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential

Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors

Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients

Shame, guilt, symptoms of depression, and reported history of psychological maltreatment

Suchergebnisse filtern